GlassScriptPhysician profile
Mhd A Alkhatib
NPI 1528115326
$7,080.98
in general payments reported to CMS, 2019-2025
24 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $231 · 2021: $889 · 2022: $1,416 · 2023: $1,261 · 2024: $1,699 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,352.66 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $729.39 | 2019-2024 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $717.69 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $576.38 | 2022-2025 | Caplyta |
| Alkermes, INC. | $573.39 | 2019-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $468.37 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $408.50 | 2019-2024 | Trintellix |
| Lundbeck LLC | $320.93 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $281.56 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $244.12 | 2019-2022 | |
| Viiv Healthcare Company | $218.55 | 2022-2025 | Cabenuva |
| Corium, LLC | $169.18 | 2021-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $149.58 | 2021-2024 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $137.53 | 2024-2025 | Auvelity |
| Tris Pharma INC | $136.24 | 2021-2025 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $132.23 | 2023-2025 | Secuado, Xelstrym |
| Shire North American Group INC | $114.27 | 2019 | |
| Neos Therapeutics, LP | $114.21 | 2022-2025 | Adzenys Xr-Odt, Metadate Cd |
| Ironshore Pharmaceuticals INC. | $104.73 | 2019-2023 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $63.83 | 2025 | Cobenfy |
| Neuronetics, INC. | $19.55 | 2019 | |
| Bausch Health US, LLC | $19.31 | 2025 | Wellbutrin, Aplenzin |
| Allergan, INC. | $14.65 | 2020 | |
| Sumitomo Pharma America, INC. | $14.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mhd Alkhatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.